Premium
Xenetic Biosciences Inc (XBIO)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.44 | -10.0456621005 | 4.38 | 4.5999 | 3.5801 | 56227 | 3.93904228 | CS |
| 4 | 0.27 | 7.35694822888 | 3.67 | 4.65 | 3.5801 | 30002 | 3.87722561 | CS |
| 12 | -0.1 | -2.47524752475 | 4.04 | 5.0899 | 3.5601 | 19316 | 3.99132915 | CS |
| 26 | 0.24 | 6.48648648649 | 3.7 | 5.2 | 2.78 | 15489 | 3.90798573 | CS |
| 52 | 0.74 | 23.125 | 3.2 | 5.2 | 2.78 | 10494 | 3.90482516 | CS |
| 156 | -11.36 | -74.2483660131 | 15.3 | 15.7 | 2.40101 | 57901 | 8.53029382 | CS |
| 260 | -6.66 | -62.8301886792 | 10.6 | 56.8 | 2.40101 | 699510 | 26.87963785 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
